Rojas SR, Richmond NJ

Language: Spanish
References: 15
Page: 40-47
PDF size: 252.72 Kb.

ABSTRACT

Background: Today ITP is still one of the most common causes of thrombocytopenia. In our country there’s a lack of studies about treatment used and its outcomes; therefore, it became a need review the type of treatments used in the different stages of the disease as well as their outcomes.
Materials and Methods: This is a descriptive, observational, longitudinal and retrospective study. Patients with ITP diagnosis from 2008 to 2012 in the Hematology Department were studied by gathering data on a recollection sheet made for this propose. They were followed for a year and response to first line treatment was described as well as the others used in relapses and refractoriness. The main results of Bone Marrow Aspirate (BMA) and coinfection with common virus were also described.
Results: 51 patients were included. There were no significant differences in first line treatment outcomes related to age, gender, comorbilities, platelet count at diagnosis or type of treatment used. 12% were refractory, but all of them responded to second line scheme no matter the drug used. Twelve patients (23%) relapsed at an average of 74.3 days. The main treatment used was prednisone, which gave the same response as others. Most BMA were normal and only 2 patients tested positive for CMV and 1 for HIV.
Conclusions: There are no differences between the first line treatment used and that recommended in guidelines. However, there was no homogeneity in the election of second and third therapeutic lines, which differ from the ones in guidelines, even so positive results obtained.

REFERENCES

1. Cines DB Liebman HA. The Inmmune Thrombocytopenia Syndrome: A Disorder of Diverse Pahogenesis and Clinical Presentation. Hematol Oncol Clin N Am. 2009;(23): 1155-1161.

2. Piccini & Nilsson. The Osler Medical Handbook, 2nd ed. 2006.

3. Hoffman: Hematology. Basic Principles and Practice, 5th ed.; Chapter 163 - The Spleen And Its Disorders.

4. Bennet CM Tarantino M. Chronic Immune Thrombocytopenia in Children: Epidemiology and Clinical Presentation. Hematol Oncol Clin N Am. 2009;(23):1223-1238.

5. Psaila B Bussel JB. Immune Thrombocytopenic Purpura. Hematol Oncol Clin N Am. 2007;(21):743-759.

6. Cines DB Blanchette VS. Immune Thrombocytopenic Purpura. N Engl J Med. 2002; (346):995-1008.

7. Kuter DJ Gernsheimer TB. Thrombopoietin and Platelet Production in Chronic Immune Thrombocytopenia. Hematol Oncol Clin N Am. 2009;(23):1193-1211.

8. Cohen YC Djulbegovic B Shamai O. The Bleeding Risk and Natural History of Idiopathic Thrombocytopenic Purpura in Patients With Persistent Low Platelet Counts. Arch Intern Med. 2000;(160):1630-1638.

9. Arkfeld DG Weitz IC. Immune Thrombocytopenia in Patients with Connective Tissue Dissorders and the Antiphospholipid Antibody Syndrome. Hematol Oncol Clin N Am. 2009;(23):1239-1249.

10. Kuwana M Okazaki Y Satoh T. Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. The American Journal of Medicine. 2005;(118):1026-1033.

11. McMillan R. Antiplatelet Antibodies in Chronic Immune Thrombocytopenia and Their Role in Platelet Destruction and Defective Platelet Production. Hematol Oncol Clin N Am. 2009;(23):1163-1175.

12. Rodeghiero F Stasi R Gernsheimer T. Standarization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;(113):2386-2393.

13. Bromberg M. Immune Thrombocytopenic Purpura – The Changing Therapeutic Landscape. N Engl J Med. 2006;(335):1643- 1645.

14. Bussel JB. Traditional and New Approaches to the Management of Immune Thrombocytopenia: Issues of When and Who to Treat. Hematol Oncol Clin N Am. 2009;(23): 1329-1341.

15. Neunert C Lim W Crowther M. The American Society of Hematology 2011 evidencie based practice guideline for immune thrombocytopenia. Blood. 2011:1-65.